Conference - Boston, MA, United States
Evaluating safety assessments and manufacturing strategies in an uncertain regulatory environment
The global pharmaceutical biological drug market is one of the fastest growing sectors generating revenue of $114.8bn in 2010, which corresponds to over 15% of the total pharmaceutical market.
There is a large and potentially lucrative demand for lower cost biological drugs worldwide.
Find out how to capitalize in this field by attending our 12th annual such event event in Boston. Click on the event link to get full conference agenda.
What are the commercial prospects for biosimilar drugs? Visiongain's report shows you potential revenues and trends to 2022, discussing data, opportunities and prospects. This study investigates biosimilars (follow-on biologics). It lets you assess forecasted sales at world market, therapeutic submarket and national level to 2022. The new report gives you coverage of regulatory affairs too - FDA, EMA and others - assessing trends and outlooks for biosimilar drugs.
(Courtesy of www.visiongain.com/Conference/349/12th-Biosimilars-Americas)
Mon, Apr 15, 2013 - Wed, Apr 17, 2013
The Seaport Hotel, Boston, USA
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
